Fountain Therapeutics

In the previous installment of Scrip Asks…What Does 2023 Hold For Biopharma? , we asked what technological advance would have the biggest impact on biopharma in 2023. Artificial intelligence was a fe

Conditions look ripe for an uptick in M&A this year after a fairly quiet 2022, while other types of strategic deals are also expected to increase in the face of a challenging funding situation for bio

With understanding of immune function advancing in leaps and bounds and a continuing proliferation of tools to manipulate it, expectations are high for advances in oncology and immunology over the com

The Alliance for Regenerative Medicine reported on 22 November that cell and gene therapy companies have raised enough money already in 2021 to break the record set in 2020. Venture capital financings